Women's Health News RSS Feed - Women's Health News

Serous ovarian cancer is more deadly, shows Cancer Research UK study

Serous ovarian cancer is more deadly, shows Cancer Research UK study

THE most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today (Tuesday) in PLOS Medicine. [More]
Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Our research into gynaecological oncology focuses around understanding mechanisms of how genes are regulated or how they become dysregulated in a disease; and also the effects that has on the surface of the endometrium and also the function of the ovaries... [More]
Study reveals how household net worth affects breast cancer care

Study reveals how household net worth affects breast cancer care

Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care. The findings suggest that physicians, health insurers, and policy makers need to pay more attention to this economic variable to ensure that breast cancer patients receive this potentially life-saving treatment. [More]
Body hang-ups prevent UK women to have health checkup, finds new HeartAge research

Body hang-ups prevent UK women to have health checkup, finds new HeartAge research

New research revealed today by HeartAge has found that almost four million British women are putting their own health at risk, as they are too embarrassed to have a health check. [More]
High ThroughputPARP in vivo Pharmacodynamic Assay

High ThroughputPARP in vivo Pharmacodynamic Assay

AMSBIO has introduced a unique High Throughput PARP in vivo Pharmacodynamic Assay that can be used to monitor the efficacy of poly-ADP-ribose polymerase (PARP) inhibitors on PAR formation in vivo; and to measure drug action on PARP in both in vivo and in vitro settings [More]
Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Christian Griesinger, director of the NMR-based Structural Biology department at the Max-Planck Institute for Biophysical Chemistry, talks about his research into neurodegenerative diseases using NMR to examine the dynamics of disordered proteins. [More]
Bayer expands patient assistance program for intrauterine devices

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria. [More]
NICE publishes Medtech Innovation Briefing on ZedScan

NICE publishes Medtech Innovation Briefing on ZedScan

The NICE MIB has been developed on ZedScan as an adjunct to colposcopy in women with suspected cervical intra-epithelial neoplasia. [More]

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient. [More]
Telephone-based peer support may help reduce postpartum depression in new mothers

Telephone-based peer support may help reduce postpartum depression in new mothers

New research reveals that telephone-based peer support may help reduce postnatal depression, also known as postpartum depression, in new mothers. Findings published in the Journal of Advanced Nursing also found that social support from peers may be effective for maternal depression up to two years after delivery. [More]
Local woman with breast cancer endorses University of Leicester's plans to transform medical education

Local woman with breast cancer endorses University of Leicester's plans to transform medical education

A 41-year-old woman from Leicester has spoken of the transformative influence of well-trained doctors as she backed the University of Leicester's Centre for Medicine Appeal, encouraging everyone to play a part in the development of a new generation of healthcare and medical education for the region. [More]
Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix™, a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores). [More]
New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

A new vaccine against HPV infections has the potential to prevent 90 per cent of all of the conditions triggered by the human papillomavirus. These are the findings of a randomised, controlled, international study involving a new, 9-component vaccine against HPV used on more than 14,000 young women aged between 16 and 26 years. [More]
VagiCap improves quality of life, satisfaction for postmenopausal women with vulvar and vaginal atrophy

VagiCap improves quality of life, satisfaction for postmenopausal women with vulvar and vaginal atrophy

Newly released patient satisfaction survey results from a study of a novel investigational vaginal estrogen treatment show promise for improving quality of life and satisfaction for postmenopausal women who experience pain during sex and other symptoms associated with vulvar and vaginal atrophy (VVA). [More]
Many women fail to understand risks of unapproved, untested bioidentical hormone therapies

Many women fail to understand risks of unapproved, untested bioidentical hormone therapies

From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society. [More]
MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention. [More]
International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

International phase 2/3 trial shows Gardasil 9 vaccine protects against nine HPV types

Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV). A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. [More]
Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. [More]
Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD). [More]
Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus. [More]